Funding Tracker/Remedy Robotics
Series B · Devices & Robotics · United States
Remedy Robotics raises $62M
Announced November 16, 2026
The round
Remedy Robotics announced a Series B round of $62M on November 16, 2026, led by DCVC. Other participants include UC Investments, Skip Capital, Hostplus, Build Collective, Blackbird, Divergent Capital, KdT Ventures.
The SignalRemedy Robotics raised a $62 million Series B led by DCVC to support N1 clinical trials, development and work toward FDA approval. N1 is under development and not available for sale or clinical use.
What Remedy Robotics does
Develops AI-enabled robotic systems for endovascular intervention.
Remedy Robotics is developing the N1 System, an AI-enabled endovascular robotic platform and software suite for on-site, remote and potential autonomous intervention. On 16 November 2026 it announced a $62 million Series B led by DCVC, supporting clinical trials, work toward FDA approval and prototype deployment with clinical partners. The company explicitly states that N1 remains under development and is not available for sale or clinical use in any jurisdiction. Dr. David Bell is CEO and co-founder.
Full Remedy Robotics profile- Company
- Remedy Robotics
- Amount
- $62M
- Stage
- Series B
- Announced
- November 16, 2026
- Led by
- DCVC
- Other investors
- UC Investments, Skip Capital, Hostplus, Build Collective, Blackbird, Divergent Capital, KdT Ventures
- Vertical
- Devices & Robotics
- Country
- United States
- Headquarters
- San Francisco, CA, United States